Sagimet Biosciences INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Sagimet Biosciences Reports Positive Phase 2b Results and Advances Denifanstat into Phase 3 Trials
Sagimet Biosciences' 10-K filing highlights the company's progress in developing denifanstat for MASH, including positive Phase 2b results and the initiation of Phase 3 clinical trials.
NASDAQ
Sagimet Biosciences' 10-K filing outlines the company's capital stock structure, registration rights, anti-takeover provisions, and compliance with securities regulations.